--- title: "RIGL.US (RIGL.US) — Related News" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/RIGL.US/news.md" symbol: "RIGL.US" name: "RIGL.US" parent: "https://longbridge.com/en/quote/RIGL.US.md" datetime: "2026-05-20T18:13:25.389Z" locales: - [en](https://longbridge.com/en/quote/RIGL.US/news.md) - [zh-CN](https://longbridge.com/zh-CN/quote/RIGL.US/news.md) - [zh-HK](https://longbridge.com/zh-HK/quote/RIGL.US/news.md) --- # RIGL.US (RIGL.US) — Related News ### [Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference | RIGL Stock News](https://longbridge.com/en/news/286413210.md) *2026-05-14T04:05:38.000Z* > Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference | RIGL Stock News ### [](https://longbridge.com/en/news/286303707.md) *2026-05-13T18:26:42.000Z* > Rigel Pharmaceuticals has entered a global licensing agreement with Arvinas and Pfizer for Veppanu, a novel cancer thera ### [These Analysts Increase Their Forecasts On Arvinas After Q1 Results](https://longbridge.com/en/news/286300592.md) *2026-05-13T17:54:35.000Z* > Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missing estimates. The company also announced a global l ### [Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target](https://longbridge.com/en/news/286287214.md) *2026-05-13T15:05:20.000Z* > H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Arvinas Holding Company, maintaining a price target of $1 ### [](https://longbridge.com/en/news/286273737.md) *2026-05-13T13:21:12.000Z* > Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to commercialize Veppanu ### [Pfizer PROTAC Licensing Deal With Rigel Adds Royalties To Valuation Story](https://longbridge.com/en/news/286183146.md) *2026-05-13T02:11:24.000Z* > Pfizer and Arvinas have licensed global rights for VEPPANU, the first FDA-approved oral PROTAC for advanced breast cance ### [](https://longbridge.com/en/news/286151833.md) *2026-05-12T19:44:34.000Z* > Rigel Pharma shares are trading higher. The company announced an exclusive, global license agreement with Arvinas and Pf ### [Analyst Reiterates Buy on Rigel as VEPPANU Acquisition Expands Portfolio; Price Target Maintained at $57](https://longbridge.com/en/news/286143464.md) *2026-05-12T17:15:24.000Z* > Analyst Joseph Pantginis from H.C. Wainwright has reiterated a Buy rating on Rigel Pharmaceuticals, maintaining a price ### [Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position](https://longbridge.com/en/news/286114895.md) *2026-05-12T14:00:46.000Z* > Rigel Pharmaceuticals' latest earnings report disappointed investors, revealing a concerning accrual ratio of 1.68, indi